Home
Charts
Search
Watchlist
Products
All IPOs
₹129 - 129
Accretion Nutraveda Ltd
PharmaceuticalsIPOSME
₹129 - 129
Accretion Nutraveda Limited, founded in 2021 in Ahmedabad, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO). The company specializes in ayurvedic and nutraceutical products including tablets, capsules, oral liquids, oral powders, external preparations and oils. Its portfolio spans diverse healthcare segments such as bone and joint care, respiratory care, gynec care, digestive care, cardiac care, liver care, paediatric care, skin and hair care, urinary and UTI care, baby care products and memory and neuron care. Operating from a 10,763 sq. ft. GMP-compliant facility in Sanand, Gujarat, the company holds ISO, WHO-GMP, and Halal certifications, ensuring global quality and safety standards.
Lot1,000Min Invest₹2,58,000Face Value₹10Issue Size₹25 CrFresh Issue₹25 CrListing Price₹191CMP₹273
Timeline
28 Jan
Bidding opens
30 Jan
Bidding closes
2 Feb
Allotment
3 Feb
Refund & demat credit
4 Feb
Listing
Subscription
Subscription opens once dates are announced
Reports
Offer Details
Terms
Issue Size₹25 Cr0.19 Cr shares
Fresh Issue₹25 Cr
Face Value₹10
Lot Size1,000 shares
ReservationQIB 49.78% · NII 15.13% · RETAIL 35.09%
Application Sizes
Retail₹2,58,0001-1 lots
sNII₹2,58,000from 2 lots
bNII₹10,32,000from 8 lots
Managers & Registrar
Lead ManagerSobhagya Capital Options Private Limited
RegistrarKFin Techologies Ltd
Ownership & Proceeds
Shareholding
CategoryPre IPOPost IPOPromoter Group92.48%55.08%Public7.52%44.92%
Objects of the Issue
- Purchase of Machineries for Automation in existing Manufacturing unit
- Purchase of Machineries for New Manufacturing Setup
- Funding working capital requirements of the company
- General corporate purposes
Financials
Profit & Loss
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| RevenueCr | 3 | 5 | 16 | 34 |
| Operating ProfitCr | 1 | 1 | 4 | 7 |
| OPM% | 21.4 | 24.4 | 23.3 | 20.5 |
| PBTCr | 0 | 1 | 3 | 6 |
| PATCr | 0 | 1 | 3 | 5 |
| EPS | 8 | 23 | 7 | 9 |
Balance Sheet
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity CapitalCr | 0 | 0 | 0 | 7 |
| ReservesCr | 0 | 1 | 5 | 28 |
| BorrowingsCr | 2 | 2 | 4 | 4 |
| Total AssetsCr | 4 | 5 | 11 | 42 |
Cash Flow
| Financial Year | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Operating Cash FlowCr | 1 | 0 | -2 | -9 |
| Investing Cash FlowCr | 0 | 0 | -1 | -15 |
| Financing Cash FlowCr | -1 | 0 | 3 | 25 |
| Net Cash FlowCr | 0 | 0 | 0 | 1 |
Strengths & Risks
Strengths · as stated in the DRHP
- Experienced Promoters and Management Team.
- Diverse Product Portfolio.
- Commitment to Quality Standards.
- Relationships with Clients and Suppliers.
- Business Processes and Management Framework.
Strategies · as stated in the DRHP
- Strengthening Sales and Marketing Network.
- Enhancing Global Presence through Direct Exports.
- Expanding and Differentiating Product Portfolio.
- Leveraging Market Relationships and Industry Engagement.
- Sustaining Competitive Advantage.
- Customer Satisfaction and Retention.
Risks · as stated in the DRHP
- The company's manufacturing operations are subject to risks, including equipment failures, accidents, and natural disasters, which could disrupt production.
- There are certain discrepancies and non-compliances noticed in some of its corporate records relating to forms filed with the Registrar of Companies, taxation authorities and other public authorities. Any penalty or action taken by any regulatory authorities in future for non- compliance with provisions of all applicable law could impact on the financial position of the Company to that extent.
- The Company is dependents on few numbers of customers for sales. Loss of any of this large customer may affect its revenues and profitability.
- The company has historically derived, and may continue to derives, a significant portion of its supply from top 10 Suppliers.
- The company's Registered Office and Factory is located on premises which are not owned by the company and has been obtained on leased. Disruption of its rights as licensee/ lessee or termination of the agreements with the company's licensors/ lessors may adversely impact its operations and, consequently,the company's business, financial condition and results of operations.
- The Company is yet to place orders for the equipment, plant and machinery for the Proposed Expansion. Any delay in placing orders or procurement of such equipment, plant and machinery may delay the schedule of implementation and possibly increase the cost of commencing operations.